IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.628
NA - Nord America 2.381
AS - Asia 2.036
SA - Sud America 389
Continente sconosciuto - Info sul continente non disponibili 210
AF - Africa 30
OC - Oceania 4
Totale 9.678
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.338
US - Stati Uniti d'America 2.309
SG - Singapore 706
CN - Cina 442
IE - Irlanda 406
BR - Brasile 334
HK - Hong Kong 318
IT - Italia 275
VN - Vietnam 273
DE - Germania 165
GB - Regno Unito 163
KR - Corea 105
IN - India 59
UA - Ucraina 47
FR - Francia 42
JP - Giappone 34
GR - Grecia 32
MX - Messico 31
FI - Finlandia 30
AR - Argentina 29
BD - Bangladesh 24
CA - Canada 24
SE - Svezia 20
PL - Polonia 19
TR - Turchia 17
AT - Austria 14
NL - Olanda 14
IQ - Iraq 12
ES - Italia 11
BE - Belgio 10
CZ - Repubblica Ceca 10
ID - Indonesia 10
EC - Ecuador 9
HU - Ungheria 7
PK - Pakistan 7
LT - Lituania 6
MA - Marocco 6
TN - Tunisia 6
CH - Svizzera 5
CR - Costa Rica 5
IL - Israele 5
ZA - Sudafrica 5
CO - Colombia 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
BO - Bolivia 3
EG - Egitto 3
JM - Giamaica 3
PT - Portogallo 3
PY - Paraguay 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BY - Bielorussia 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PE - Perù 2
PR - Porto Rico 2
UZ - Uzbekistan 2
VE - Venezuela 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GT - Guatemala 1
IR - Iran 1
IS - Islanda 1
KZ - Kazakistan 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.469
Salva come PNG Salva come JPEG
Città #
Moscow 1.165
San Jose 410
Dublin 404
Santa Clara 316
Hong Kong 313
Singapore 291
Chandler 148
Ashburn 138
Seoul 104
Ho Chi Minh City 100
Dallas 96
Hefei 87
Council Bluffs 85
Jacksonville 80
Beijing 73
Hanoi 56
Munich 55
Princeton 54
Roxbury 53
New York 52
Bremen 46
Naples 44
Caserta 42
Los Angeles 41
The Dalles 36
Ann Arbor 32
Bengaluru 32
Cambridge 30
Medford 30
São Paulo 30
Redhill 26
Memphis 21
Milan 19
Boardman 18
Da Nang 16
Warsaw 16
Wilmington 16
Des Moines 15
Aversa 14
Nuremberg 13
Rio de Janeiro 13
Haiphong 12
Helsinki 12
Norwalk 12
Phoenix 12
Brussels 10
Mexico City 10
Rome 10
San Francisco 10
Turku 10
Falkenstein 9
Toronto 9
Atlanta 8
Boston 8
Frankfurt am Main 8
Houston 8
Ninh Bình 8
Orem 8
Amsterdam 7
Belo Horizonte 7
Chicago 7
Kochi 7
Nanjing 7
Stockholm 7
Tokyo 7
Ankara 6
Denver 6
Miami 6
Redwood City 6
San Mateo 6
Seattle 6
Thái Bình 6
Tianjin 6
Vienna 6
Brasília 5
Buffalo 5
Casablanca 5
Chennai 5
Guarulhos 5
Jinan 5
London 5
Mountain View 5
Quảng Ngãi 5
Salto 5
Baghdad 4
Brooklyn 4
Can Tho 4
Cercola 4
Columbus 4
Curitiba 4
Guangzhou 4
Hyderabad 4
Jakarta 4
Marcianise 4
Montreal 4
Nanchang 4
Ottawa 4
Phú Nhuận 4
Prague 4
Quito 4
Totale 5.011
Salva come PNG Salva come JPEG
Nome #
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 178
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 169
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 167
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 163
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 162
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 160
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 160
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 155
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 155
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 155
Is the pathology of posterior cortical atrophy clinically predictable? 152
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 151
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 149
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 148
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 147
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 145
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 145
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 143
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 142
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 142
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 141
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 141
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 140
Clinical activity after fingolimod cessation: disease reactivation or rebound? 139
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 136
Disability assessment using Google Maps 134
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 133
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 132
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 132
Signs and symptoms of COVID-19 in patients with multiple sclerosis 131
A real-world study of alemtuzumab in a cohort of Italian patients 131
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 130
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 126
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 126
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 123
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 122
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 121
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 120
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 120
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis 119
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 118
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 115
Migraine as possible red flag of PFO presence in suspected demyelinating disease 115
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 113
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 110
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 109
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 108
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 106
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 105
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 102
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 102
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 102
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 100
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 99
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 99
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 99
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 99
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 97
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 97
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 95
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 93
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 92
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 92
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 90
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 90
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue 87
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 86
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 86
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 85
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 85
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 79
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 79
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 78
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 78
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 78
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 77
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 74
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 73
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 73
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 68
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 67
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 65
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 65
Theory of mind in multiple sclerosis: Three-month follow-up effects after double-blind tDCS and video-training, a pilot study 33
Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm 24
FCGR3A Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab 6
Totale 9.678
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022371 0 0 3 12 99 7 10 8 30 50 25 127
2022/2023701 72 18 9 45 79 42 0 35 353 6 23 19
2023/2024376 23 11 22 21 107 41 33 5 8 3 24 78
2024/20251.432 2 22 8 47 210 194 150 125 228 208 136 102
2025/20265.875 193 291 356 281 498 3.095 346 258 193 143 140 81
2026/2027371 48 168 155 0 0 0 0 0 0 0 0 0
Totale 9.678